National "Major New Drug Creation" Achievement Dabohua Approved for Listing Can "Kill" Tumor Cells Accurately
Chinanews.com, Suzhou, October 9 (Wang Min) On October 9, the anti-tumor drug Dabohua was officially approved by the National Medical Products Administration.
The drug is used to treat diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, etc.
Zhou Hui, vice president of Cinda's Biomedical Science and Strategic Oncology Department, said that as a result of the country’s “significant new drug creation”, the listing of Tubohua will effectively reduce the cost of medication for related patients, improve the availability of clinical medication, and better satisfy the common people. Demand for high-quality biological drugs.
Malignant lymphoma is the most common hematological malignant tumor, and its incidence has been on the rise in recent years.
Diffuse large B-cell lymphoma, follicular lymphoma, and chronic lymphocytic leukemia are all B-cell non-Hodgkin lymphomas.
The expression of CD20 on the surface of tumor cells is a common feature of these diseases.
Zhou Hui said that Dubohua is a monoclonal antibody that targets CD20.
He described it as a guided missile, which is precisely combined with CD20 molecules. On the one hand, it activates immune cells, thereby allowing immune cells to produce cytotoxic effects, causing tumor cells to collapse and destroy, and ultimately "kill" tumor cells; on the other hand, activation The complement protein in the human immune system forms a "siege" situation on tumor cells and "tears them to pieces", eventually leading to tumor cell apoptosis.
According to another report, Rituximab, developed by Genentech, a subsidiary of Roche Pharmaceuticals, is the first monoclonal antibody drug for the treatment of cancer and was launched in China in 2000.
However, because many patients cannot afford the cost of imported medicines, they are unable to receive good treatment.
Dabohua's approval for listing also means that more Chinese patients will be provided with high-quality and affordable rituximab injections.
Dabohua was jointly developed by Cinda Biopharmaceutical Group and Eli Lilly Pharmaceutical Group.
This is also the fourth monoclonal antibody drug approved for marketing by Cinda Biotech after Daboshu, Dayotong and Su Lixin.
Zhou Hui said that monoclonal antibody drugs have the characteristics of high specificity, strong targeting and low side effects, and are sought after by many international pharmaceutical companies.
Since its establishment in 2011, they have set the goal of developing high-quality bio-innovative drugs with international standards, focusing on the field of antibody drugs, and deploying multiple monoclonal antibody drugs.
(Finish)